Related Experiment Videos
Pneumococcal polysaccharide vaccines
1Department of Research Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
Insights
Pneumococcal infections cause significant childhood illness and death. Vaccines using polysaccharide-protein conjugates in infancy, followed by polysaccharide vaccines later, show promise in preventing these infections.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Pneumococcal infections are a leading cause of childhood morbidity and mortality globally.
- Increasing antibiotic resistance in pneumococci necessitates effective prophylactic strategies.
- Immune system maturation in children affects vaccine responsiveness to bacterial polysaccharides.
Purpose of the Study:
- To evaluate the efficacy of novel pneumococcal vaccines in early childhood.
- To explore strategies for enhancing immunogenicity and immune memory against pneumococcal serotypes.
- To reduce the future incidence of pneumococcal infections through immunization.
Main Methods:
- Investigating the immunogenicity of polysaccharide-protein conjugate vaccines in infants.
- Assessing the development of IgM and IgG antibodies and immunologic memory.
- Studying the responsiveness to purified polysaccharide vaccines after age 10.
Main Results:
- Polysaccharide-protein conjugate vaccines are immunogenic in infancy.
- These conjugate vaccines stimulate robust IgM and IgG antibody production and immunologic memory.
- A combined vaccination strategy shows potential for significant infection reduction.
Conclusions:
- Vaccination with polysaccharide-protein conjugates in infancy is effective.
- Subsequent administration of purified polysaccharide vaccines after age 10 enhances protection.
- This immunization schedule offers a promising approach to reduce pneumococcal disease burden in children.
Abstract:
Pneumococcal infections are major causes of morbidity and mortality in children throughout the world. For this reason and because of the increasingly frequent isolation of multiply resistant pneumococci of the serotypes most often causing infection in childhood, prophylactic immunization offers the best prospect of reducing the incidence of such infections in the future. Studies of the immune system of humans have shown that immunologic maturation continues throughout the first decade of life and that responsiveness to some purified bacterial polysaccharides may be delayed until several years after birth. Vaccines of such capsular polysaccharides conjugated chemically to protein have been found to be immunogenic at an earlier age and to stimulate the development of IgM and IgG antibodies and of "immunologic memory." Current investigations suggest that administration of polyvalent vaccines of polysaccharide-protein conjugates in infancy followed by the administration of vaccines of purified polysaccharides after the age of 10 years offers the prospect of reducing significantly the incidence of pneumococcal infections.